Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 23;39:256. doi: 10.1186/s13046-020-01772-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — miR-29b-3p deficiency was associated with reduced degradation of VANGL1 mRNA. a Starbase web showing miR-15b-5p, miR-29b-3p and miR-200a-3p expression in LUAD and normal lung tissues. ***P < 0.001 vs. normal tissues. Unpaired two-tailed t-tests (n = 526). b Starbase web showing the correlation of VANGL1 expression with miR-15b-5p, miR-29b-3p and miR-200a-3p expression in LUAD. c Gepia web showing the survival time and percentage of survival in LUAD patients with high or low levels of miR-15b-5p, miR-29b-3p and miR-200a-3p. d Expression of miR-15b-5p, miR-29b-3p and miR-200a-3p was tested in LUAD cells after exposing different dosages of irradiation. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. 0 Gy. One-way analysis of variance (ANOVA) with post-hoc Dunnett’s testing (n = 3). LUAD cells were transfected with inhibitors of miR-15b-5p, miR-29b-3p and miR-200a-3p. In addition, LUAD cells were transfected with mimics of these miRNAs, followed by 2 Gy irradiation. After these treatments, cells were subjected to (e) PCR and (f) western blot assays. *P < 0.05, and ***P < 0.001 vs. control group; ^#P < 0.05, and ^##P < 0.01 vs. 2 Gy group. In this group, cells were only treated with 2 Gy irradiation. One-way analysis of variance (ANOVA) with post-hoc Dunnett’s testing (n = 3). g Luciferase report assay was performed to determine whether VANGL1 is a target of miR-29b-3p. **P < 0.01 vs. WT group. Unpaired two-tailed t-tests (n = 3). h The serum level of hsa-miR-29b-3p in patients with LUAD before and after radiotherapy. Ha: the green and red dots represent the serum level of hsa-miR-29b-3p in patients with LUAD before and after radiotherapy, respectively. The green and red dots belonging to the same patient were connected by a line. Hb: the bar chart of hsa-miR-29b-3p serum level. ***P < 0.001 between before and after radiotherapy. Paired two-tailed t-tests (n = 36)